Clinical Trial Update: A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 prevention trial of canakinumab in high-risk individuals for lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Lung Cancer | Phase 3 | Status: TERMINATED